Bionter AG, experts in sub-visible particle testing, the completion of a $3 million Series Seed financing from Dynamk Capital.
Bionter revolutionizes analytical testing of subvisible particles in the biopharmaceutical industry in respect to economy, process time and safety.
Proceeds from this round will help the company to expand their committed team, launch their first solution in 2022 ,and fuel their pipeline with new innovative developments.
"Bionter technology is a game changer in subvisible particle counting, one of the most important quality attributes of administered liquid biologics," said Reinhard Vogt, chair of the Board of Bionter and Venture Partner at Dynamk Capital"
The financing accelerates the already exceptional momentum for Bionter's initial offering. Bionter's complete solution includes a particle counter supported with single-use consumables, maintenance and training, applicable for biotech's drug product sector and based on a new combination light obscuration technology and smart automation.
A challenge faced by the biopharmaceutical industry is how to minimize the amount of costly sample required to determine particle count. Bionter's device reduces the overall sample volume required, saving material for other analytical endpoints, hence reducing costs.
Its smart automated workflow drives efficiency, minimizes human interaction and therefore improving reliability, data integrity and in turn patient safety. Bionter's particle counter is also compliant to current USP/EP/JP regulations familiar with manufacturers.
The company has completed development of its patented technology and will launch it end of May 2022.
"This financing enables us to bring our first product to our customers while driving the development of new innovations," said Dr. Tobias Werk, CEO of Bionter. "We are thrilled to have Dynamk Capital join our team, as they provide a wealth of experience growing life science tools companies and help position Bionter and help us to make our vision a reality."
About Dynamk Capital:
Dynamk Capital is a growth equity and venture capital firm focused on life sciences industrials. Dynamk's investment strategy is centered on identifying companies developing disruptive technologies, tools, and services that enable the full biopharma continuum across discovery, development, and manufacturing of biotherapeutics, including cell & gene therapies and vaccines.
